Fintel reports that on December 16, 2025, UBS maintained coverage of NeuroPace (NasdaqGM:NPCE) with a Buy recommendation.
Analyst Price Forecast Suggests 12.12% Upside
As of December 6, 2025, the average one-year price target for NeuroPace is $17.85/share. The forecasts range from a low of $15.15 to a high of $21.00. The average price target represents an increase of 12.12% from its latest reported closing price of $15.92 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for NeuroPace is 73MM, a decrease of 23.57%. The projected annual non-GAAP EPS is -1.83.
What is the Fund Sentiment?
There are 185 funds or institutions reporting positions in NeuroPace. This is an decrease of 22 owner(s) or 10.63% in the last quarter. Average portfolio weight of all funds dedicated to NPCE is 0.08%, an increase of 0.40%. Total shares owned by institutions increased in the last three months by 13.16% to 27,271K shares. 
The put/call ratio of NPCE is 0.29, indicating a bullish outlook.
What are Other Shareholders Doing?
Polar Capital Holdings holds 3,098K shares representing 9.30% ownership of the company. In its prior filing, the firm reported owning 0K shares , representing an increase of 100.00%.
Soleus Capital Management holds 2,958K shares representing 8.88% ownership of the company. In its prior filing, the firm reported owning 2,313K shares , representing an increase of 21.81%. The firm decreased its portfolio allocation in NPCE by 10.02% over the last quarter.
Orbimed Advisors holds 2,614K shares representing 7.85% ownership of the company. No change in the last quarter.
First Light Asset Management holds 1,360K shares representing 4.08% ownership of the company. In its prior filing, the firm reported owning 1,380K shares , representing a decrease of 1.50%. The firm decreased its portfolio allocation in NPCE by 33.70% over the last quarter.
Armistice Capital holds 1,298K shares representing 3.90% ownership of the company. In its prior filing, the firm reported owning 1,152K shares , representing an increase of 11.22%. The firm decreased its portfolio allocation in NPCE by 26.00% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
